50332-66-6

Basic information

• Product Name: 3-NITRO-4-QUINOLINOL
• Synonyms: 4-QUINOLINOL, 3-NITRO-;4-HYDROXY-3-NITROQUINOLINE;3-NITRO-4-QUINOLINOL;3-NITRO-4-HYDROXYQUINOLINE;3-NITROQUINOLIN-4-OL;3-Nitro-4-Hydroxy quinolin;3-Nitro-4-hydroxyquinoline ,97%;4(1H)-quinolinone, 3-nitro-
• CAS NO: 50332-66-6
• Molecular Formula: C₉H₆N₂O₃
• Molecular Weight: 190.16
• Product Categories: pharmacetical;Heterocyclic Compounds;Heterocycles
• Mol File: 50332-66-6.mol
• Article Data: 23

Chemical Properties

• Melting Point: >3000C
• Boiling Point: 312.3 °C at 760 mmHg
• Flash Point: 142.7 °C
• Appearance: Tan Solid
• Density: 1.45 g/cm³
• Vapor Pressure: 0.000534mmHg at 25°C
• Refractive Index: 1.657
• Storage Temp.: Refrigerator
• Solubility: DMF (Slightly), DMSO (Slightly)
• PKA: -0.02±0.50(Predicted)
• Stability: <-200C
• CAS DataBase Reference: 3-NITRO-4-QUINOLINOL(CAS DataBase Reference)
• NIST Chemistry Reference: 3-NITRO-4-QUINOLINOL(50332-66-6)
• EPA Substance Registry System: 3-NITRO-4-QUINOLINOL(50332-66-6)

Safety Data

• Statements: 25-37-38-41
• Safety Statements: 26-36/37/39
• RIDADR: 2811
• HazardClass: IRRITANT
• Hazardous Substances Data: 50332-66-6(Hazardous Substances Data)

Usage

Chemical Properties

Tan Solid

Uses

3-Nitro-4-hydroxyquinoline (cas# 50332-66-6) is a compound useful in organic synthesis.

InChI:InChI=1/C9H6N2O3/c12-9-6-3-1-2-4-7(6)10-5-8(9)11(13)14/h1-5H,(H,10,12)

Upstream product

• 121845-92-9 2-<2-nitroethylideneamino>benzoic acid 
• 2099-63-0 anthranilic acid hydrochloride 
• 118-92-3 anthranilic acid 
• 529-37-3 4(1H)-quinolinone 
• 7697-37-2 nitric acid 
• 56-57-5 4-nitroquinoline-N-oxide 
• 108-24-7 acetic anhydride 
• 611-36-9 quinolin-4-ol 

Downstream Products

• 103862-98-2 N-(4-hydroxyquinolin-3-yl)acetamide 
• 24220-95-9 1-Methyl-3-nitro-4-chinolon 
• 99512-72-8 3-amino-4-hydroxyquinoline 
• 39061-97-7 4-chloro-3-nitroquinoline 
• 874499-33-9 3,6-dinitro-quinolin-4-ol 
• 99009-85-5 N-(2-methylpropyl)-3-nitro-4-quinolinamine 
• 1080009-67-1 methyl 2-(4-((N-(3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl)-2-(dimethylamino)acetamido)methyl)phenyl)acetate monosaccharin salt 
• 1080009-76-2 methyl 2-(4-((N-(3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl)-2-(dimethylamino)acetamido)methyl)phenyl)acetate mandelic acid salt 
• 1080009-78-4 methyl 2-(4-((N-(3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl)-2-(dimethylamino)acetamido)methyl)phenyl)acetate fumaric acid salt 
• 1080007-62-0 2-(4-(((3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl)(1-methylpiperidin-4-yl)amino)methyl)phenyl)acetic acid 
• 1080007-89-1 methyl 2-(4-((N-(3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl)-2-(methylsulfonyl)acetamido)methyl)phenyl)acetate 
• 1080007-55-1 methyl 2-(3-(((3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl)(1-methylpiperidin-4-yl)amino)methyl)phenyl)acetate 
• 1080007-60-8 methyl 2-(4-(((3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl)(1-methylpiperidin-4-yl)amino)methyl)phenyl)acetate 
• 1080007-67-5 methyl 2-(3-(((3-(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl)(3-(dimethylamino)propyl)amino)methyl)phenyl)acetate 

Relevant articles and documents

IMIDAZOQUINOLINE-TYPE COMPOUNDS AND USES THEREOF

Provided in the present disclosure are imidazoquinoline-type compounds, methods for their preparation, pharmaceutical compositions thereof and their use, wherein the imidazoquinoline-type compounds, upon local administration, form depots inducing cell mediated immune response while mitigating a systemic proinflammatory immune response.

Design, synthesis, and biological activity of TLR7-based compounds for chemotherapy-induced alopecia

Hair loss is a common dermatosis symptom and side-effect in cancer chemotherapeutics. Imiquimod application at mid and late telogen activated the hair follicle stem cells leading to premature hair cycle entry. Based on quinoline structure, a newly synthesized compound 6b displayed proliferation activity in vitro and in vivo through branch chain replacement and triazole ring cyclization. Toll-like receptors (TLRs) are also critical mediators of the immune system, and their activation is linked to various diseases. The present study aimed to expand new agonists within co-crystallization of TLR7 (PDB code: 5GMH); however, biological assays of NF-κB activity and NO-inhibition indicated that five selected compounds were TLR7 antagonists. Molecular docking indicated the binding mode differences: antagonists binding TLR7 in a different direction and interacting with adjacent TLR7 with difficulty in forming dimers.

SUBSTITUTED IMIDAZOQUINOLINES AS AGONISTS OF TLR7

The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines.